Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05EVI
|
|||
| Former ID |
DNC011862
|
|||
| Drug Name |
U-78875
|
|||
| Synonyms |
PANADIPLON; 124423-84-3; U-78875; UNII-V4PW0S7ZP7; V4PW0S7ZP7; FG-10571; CHEMBL279867; Panadiplonum; Panadiplone; AC1MHWDJ; Panadiplon (USAN/INN); Panadiplon (U-78875); SCHEMBL123304; ZINC4220; DTXSID40869698; BDBM50048837; AKOS015904452; RL01109; API0007797; ZB000564; D05346; J-523865; 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-propan-2-ylimidazo[1,5-a]quinoxalin-4-one; 3-(5-Cyclopropyl-[1,2,4]oxadiazol-3-yl)-5-isopropyl-5H-imidazo[1,5-a]quinoxalin-4-one
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Anxiety disorder [ICD-11: 6B00-6B0Z; ICD-10: R45.0] | Discontinued in Phase 1 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H17N5O2
|
|||
| Canonical SMILES |
CC(C)N1C2=CC=CC=C2N3C=NC(=C3C1=O)C4=NOC(=N4)C5CC5
|
|||
| InChI |
1S/C18H17N5O2/c1-10(2)23-13-6-4-3-5-12(13)22-9-19-14(15(22)18(23)24)16-20-17(25-21-16)11-7-8-11/h3-6,9-11H,7-8H2,1-2H3
|
|||
| InChIKey |
ZGEGOFCLSWVVKG-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 124423-84-3
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | GABA(A) receptor alpha-1 (GABRA1) | Target Info | Inhibitor | [2] |
| GABA(A) receptor beta-2 (GABRB2) | Target Info | Inhibitor | [3] | |
| GABA(A) receptor gamma-2 (GABRG2) | Target Info | Inhibitor | [4] | |
| Gamma-aminobutyric acid receptor (GAR) | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Retrograde endocannabinoid signaling | ||||
| GABAergic synapse | ||||
| Morphine addiction | ||||
| Nicotine addiction | ||||
| Serotonergic synapse | ||||
| Reactome | Ligand-gated ion channel transport | |||
| GABA A receptor activation | ||||
| WikiPathways | Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||
| Iron uptake and transport | ||||
| SIDS Susceptibility Pathways | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001194) | |||
| REF 2 | Piperazine imidazo[1,5-a]quinoxaline ureas as high-affinity GABAA ligands of dual functionality. J Med Chem. 1999 Apr 8;42(7):1123-44. | |||
| REF 3 | High-affinity alpha-aminobutyric acid A/benzodiazepine ligands: synthesis and structure-activity relationship studies of a new series of tetracycli... J Med Chem. 1996 Nov 8;39(23):4654-66. | |||
| REF 4 | 3-Phenyl-substituted imidazo[1,5-alpha]quinoxalin-4-ones and imidazo[1,5-alpha]quinoxaline ureas that have high affinity at the GABAA/benzodiazepin... J Med Chem. 1996 Sep 13;39(19):3820-36. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.